D patients and in baseline comorbidity subgroups<p><b>Copyright information:</b></p><p>Taken from "The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity"</p><p></p><p>International Journal of Clinical Practice 2007;61(8):1283-1293.</p><p>Published online Jan 2007</p><p>PMCID:PMC2408656.</p><p>© 2007 The Authors Journal compilation 2007 Blackwell Publishing Ltd</p
Abstract Background Major depression significantly impairs quality of life, increases the risk of su...
Duloxetine is a serotonin-noradrenaline reuptake inhibitor with established efficacy for the short-t...
About 21% of adults with osteoarthritis (OA) are diagnosed with concomitant depression in addition t...
Ndomised patients and in baseline comorbidity subgroups<p><b>Copyright information:</b></p><p>Taken ...
(B) Effects of duloxetine compared with placebo on HAMD total score: mean change analysis in all ran...
International audienceBACKGROUND: Duloxetine is an antidepressant that benefits from a wide range of...
BACKGROUND: Major depressive disorder (MDD) is a common condition in the elderly that is frequently ...
OBJECTIVE: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is curre...
Abstract Background Late-life depression is a common, chronic and recurring disorder for which guide...
BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms o...
The elderly population is more frequently subjected to depressive mood compared to the general popul...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD...
Objective: Major depressive disorder (MDD) is a significant public health concern and challenges hea...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
Abstract Background Major depression significantly impairs quality of life, increases the risk of su...
Duloxetine is a serotonin-noradrenaline reuptake inhibitor with established efficacy for the short-t...
About 21% of adults with osteoarthritis (OA) are diagnosed with concomitant depression in addition t...
Ndomised patients and in baseline comorbidity subgroups<p><b>Copyright information:</b></p><p>Taken ...
(B) Effects of duloxetine compared with placebo on HAMD total score: mean change analysis in all ran...
International audienceBACKGROUND: Duloxetine is an antidepressant that benefits from a wide range of...
BACKGROUND: Major depressive disorder (MDD) is a common condition in the elderly that is frequently ...
OBJECTIVE: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is curre...
Abstract Background Late-life depression is a common, chronic and recurring disorder for which guide...
BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms o...
The elderly population is more frequently subjected to depressive mood compared to the general popul...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD...
Objective: Major depressive disorder (MDD) is a significant public health concern and challenges hea...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
Abstract Background Major depression significantly impairs quality of life, increases the risk of su...
Duloxetine is a serotonin-noradrenaline reuptake inhibitor with established efficacy for the short-t...
About 21% of adults with osteoarthritis (OA) are diagnosed with concomitant depression in addition t...